Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
2.
3.

Enhancing the efficacy of hormonal agents with selected targeted agents.

Johnston SR.

Clin Breast Cancer. 2009 Jun;9 Suppl 1:S28-36. doi: 10.3816/CBC.2009.s.003. Review.

PMID:
19561004
4.

Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.

Dixon JM, Jackson J, Renshaw L, Miller WR.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):295-9. Review.

PMID:
14623524
5.

Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.

Dodwell D, Williamson D.

Cancer Treat Rev. 2008 Apr;34(2):137-44. Epub 2007 Nov 14. Review.

PMID:
18006236
6.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

7.

Understanding the BIG results: Insights from the BIG 1-98 trial analyses.

Wardley AM.

Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Review.

PMID:
19096768
8.

Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.

Iwata H.

Breast Cancer. 2011 Apr;18(2):92-7. doi: 10.1007/s12282-010-0233-6. Epub 2010 Dec 8. Review.

PMID:
21140250
9.

Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.

Ellis MJ, Rosen E, Dressman H, Marks J.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):301-7. Review.

PMID:
14623525
10.

Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.

Monnier A.

Expert Rev Anticancer Ther. 2006 Oct;6(10):1355-9. Review.

PMID:
17069521
12.

A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.

Jerusalem G, Bachelot T, Barrios C, Neven P, Di Leo A, Janni W, de Boer R.

Cancer Treat Rev. 2015 Feb;41(2):94-104. doi: 10.1016/j.ctrv.2014.12.011. Epub 2014 Dec 30. Review.

PMID:
25575443
13.

Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?

Takei H, Kurosumi M, Yoshida T, Hayashi Y, Higuchi T, Uchida S, Ninomiya J, Oba H, Inoue K, Nagai S, Tabei T.

Breast Cancer. 2011 Apr;18(2):85-91. doi: 10.1007/s12282-010-0239-0. Epub 2010 Nov 23. Review.

PMID:
21104350
14.
15.

Preoperative systemic treatment: prediction of responsiveness.

Colleoni M, Zahrieh D, Gelber RD, Viale G, Luini A, Veronesi P, Intra M, Galimberti V, Renne G, Goldhirsch A.

Breast. 2003 Dec;12(6):538-42. Review. Erratum in: Breast. 2004 Jun;13(3):263. Zarieh D [corrected to Zahrieh D].

PMID:
14659132
16.

Neoadjuvant endocrine therapy in primary breast cancer.

Huober J, Krainick-Strobel U, Kurek R, Wallwiener D.

Clin Breast Cancer. 2004 Dec;5(5):341-7. Review.

PMID:
15585070
17.

Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making?

Puglisi F, Minisini AM.

Crit Rev Oncol Hematol. 2011 Feb;77(2):87-99. doi: 10.1016/j.critrevonc.2010.01.006. Epub 2010 Feb 4. Review.

PMID:
20133149
18.

Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.

Colleoni M, Viale G, Goldhirsch A.

Breast. 2009 Oct;18 Suppl 3:S137-40. doi: 10.1016/S0960-9776(09)70289-9. Review.

PMID:
19914533
19.

Update on the use of letrozole in breast cancer.

Wu M, Goss PE.

Expert Opin Pharmacother. 2007 Oct;8(14):2329-45. Review.

PMID:
17927487

Supplemental Content

Support Center